



## Sofinnova Partners Re-joins Board of Directors

**Paris, October 3, 2019** – 7:00 AM CEST - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, today announced the co-optation of Sofinnova Partners to its Board of Directors, represented by Mr. Gérard Hascoët, replacing Mr. James Reinstein. Sofinnova Partners, a major historical investor in Pixium Vision, had a Director's seat from 2014 to 2017 and Observer's seat since 2017.

**Bernard Gilly, Chairman of the Board and co-founder**, stated: *"We are very glad to welcome Sofinnova Partners and its representative Gérard Hascoët as Director of Pixium Vision. Sofinnova Partners is one of our cornerstone investors and major financial supporters alongside Bpifrance. We would like to extend our deepest gratitude to James Reinstein for his dedicated service to the Board of Directors of Pixium Vision."*

**Gérard Hascoët, representing Sofinnova Partners**, commented: *"As part of its primary mission in financing innovation in healthcare, Sofinnova Partners is very proud to support Pixium Vision on its journey to restore vision to those who have lost their sight. Getting back our Directorship highlights our willingness to continue to support the development of Pixium Vision and its Prima System in patients losing vision from dry age-related macular degeneration (AMD), a large unmet medical need."*

Sofinnova Partners will be presented for confirmation at the Annual General Meeting.

### Contacts

#### **Pixium Vision**

Didier Laurens  
Chief Financial Officer  
[investors@pixium-vision.com](mailto:investors@pixium-vision.com)  
+33 1 76 21 47 68

#### **Media relations**

**LifeSci Advisors**  
Sophie Baumont  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)  
+33 6 27 74 74 49

#### **Investors relation**

**LifeSci Advisors**  
Chris Maggos  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+41 79 367 62 54

**Pixium Vision** is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information, please visit: <http://www.pixium-vision.com/fr>

And follow us on : [@PixiumVision](https://twitter.com/PixiumVision); [www.facebook.com/pixiumvision](https://www.facebook.com/pixiumvision)

[Linkedin www.linkedin.com/company/pixium-vision](https://www.linkedin.com/company/pixium-vision)



Pixium Vision is listed on Euronext Paris (Compartment C).

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index  
Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA –

### **Disclaimer:**

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements. Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise. For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number D.19-0364 on April 18, 2019 which can be found on the websites of the AMF - AMF ([www.amf-france.org](http://www.amf-france.org)) and of Pixium Vision ([www.pixium-vision.com](http://www.pixium-vision.com)).